PCI-32765

ibrutinib · Pharmacyclics

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for PCI-32765, covering 2013-05-22 to 2021-05-07. Get the full timeline:

Most recent: Clinical Trial Update: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma [Phase 2]